Modulation of inflammatory response in mice with severe autoimmune disease by thymic peptide thymulin and an inhibitor of NF-kappaB signalling.

Lunin SM, Khrenov MO, Novoselova TV, Parfenyuk SB, Glushkova OV, Fesenko EE, Novoselova EG

International immunopharmacology7 Feb 2015Cited by 11 (Europe PMC)

PMID25662754DOI10.1016/j.intimp.2015.01.021PepBankPUB-25662754

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with severe EAE, thymulin reduced disease severity.
In plain wordsIn mice with severe EAE, thymulin reduced disease severity.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseDisease severity
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
0.15mg/kg e.o.d · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Both the IKK Inhibitor XII and thymulin reduced disease severity, attenuated immune imbalance, and increased mouse life-span.
1 context sentence(design, population, supporting numbers)
Summary · context
an inhibitor of NF-kappaB signalling, IKK Inhibitor XII, and/or thymic peptide thymulin, were injected intraperitoneally at 1.8 and 0.15mg/kg e.o.d, respectively,
Report a problemFND-2566275401
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with severe EAE, thymulin attenuated immune imbalance.
In plain wordsIn mice with severe EAE, thymulin reduced immune imbalance.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseImmune imbalance
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Immune response · Immune and inflammation
Studied dose
0.15mg/kg e.o.d · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Both the IKK Inhibitor XII and thymulin reduced disease severity, attenuated immune imbalance, and increased mouse life-span.
1 context sentence(design, population, supporting numbers)
Summary · context
an inhibitor of NF-kappaB signalling, IKK Inhibitor XII, and/or thymic peptide thymulin, were injected intraperitoneally at 1.8 and 0.15mg/kg e.o.d, respectively,
Report a problemFND-2566275402
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with severe EAE, thymulin increased life-span.
In plain wordsIn mice with severe EAE, thymulin increased life-span.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseLife-span
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Mortality · Whole body
Studied dose
0.15mg/kg e.o.d · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Both the IKK Inhibitor XII and thymulin reduced disease severity, attenuated immune imbalance, and increased mouse life-span.
1 context sentence(design, population, supporting numbers)
Summary · context
an inhibitor of NF-kappaB signalling, IKK Inhibitor XII, and/or thymic peptide thymulin, were injected intraperitoneally at 1.8 and 0.15mg/kg e.o.d, respectively,
Report a problemFND-2566275403
04AnimalAnimal study (in vivo)Mechanism
In mice with severe EAE, thymulin reduced the Th1 response.
In plain wordsIn mice with severe EAE, thymulin reduced the Th1 immune response.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseTh1 response
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Immune response · Immune and inflammation
Studied dose
0.15mg/kg e.o.d · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Both the inhibitor and thymulin reduced the Th1 response but not the Th17 response.
1 context sentence(design, population, supporting numbers)
Summary · context
an inhibitor of NF-kappaB signalling, IKK Inhibitor XII, and/or thymic peptide thymulin, were injected intraperitoneally at 1.8 and 0.15mg/kg e.o.d, respectively,
Report a problemFND-2566275405
05AnimalAnimal study (in vivo)Mechanism
In mice with severe EAE, thymulin did not reduce the Th17 response.
In plain wordsIn mice with severe EAE, thymulin did not reduce the Th17 immune response.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeTh17 response
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Immune response · Immune and inflammation
Studied dose
0.15mg/kg e.o.d · intraperitonealAs given in this study (mouse).
Source sentences
Summary
Both the inhibitor and thymulin reduced the Th1 response but not the Th17 response.
1 context sentence(design, population, supporting numbers)
Summary · context
an inhibitor of NF-kappaB signalling, IKK Inhibitor XII, and/or thymic peptide thymulin, were injected intraperitoneally at 1.8 and 0.15mg/kg e.o.d, respectively,
Report a problemFND-2566275406

Studies that did not test the peptide alone1

In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymulin (serum thymic factor).

06AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Efficacy outcome
In mice with severe EAE, co-administration of thymulin and IKK Inhibitor XII produced no additive effect.
In plain wordsIn mice with severe EAE, thymulin with IKK Inhibitor XII produced no additive effect.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeAdditive effect of co-administration
Study
mousen: not reported in source
Severe experimental autoimmune encephalomyelitis in C57BL/6 mice
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Co-administration of the agents produced no additive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
Both the IKK Inhibitor XII and thymulin reduced disease severity, attenuated immune imbalance, and increased mouse life-span.
In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).
Report a problemFND-2566275404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:55 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.